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Abstract ZAP-70 is a protein tyrosine kinase (PTK) that plays 
a critical role in T cell activation. To study the role of ZAP-70 
catalytic activity in this process, a substrate capable of 
distinguishing between the activities of ZAP-70 and other PTKs 
would be useful, especially since it has recently been shown that 
ZAP-70 interacts with another T cell PTK, Lck. We have thus 
identified a site of phosphorylation on the cytoplasmic fragment 
of the erythrocyte band 3 protein that is recognized by ZAP-70, 
but not Lck. A synthetic peptide based on this site has been 
demonstrated to be a good in vitro substrate for ZAP-70 and a 
poor substrate for the T cell PTKs Lck and Itk. This peptide 
molecule should thus prove useful to many investigators working 
in the field of T cell activation. 
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1. Introduction 
ZAP-70 is a T cell specific protein tyrosine kinase (PTK) 
known to play a critical role in the activation of T cells via 
their antigen receptor (TCR). Upon TCR engagement, a num- 
ber of PTKs become activated, and a wide range of cellular 
substrates, including some of the TCR subunits, become tyr- 
osine phosphorylated (for recent reviews of TCR structure, 
function and its associated PTKs, see [1-3]). Notable among 
these is the TCR ~ subunit, which contains 6 tyrosines in its 
cytoplasmic domain. All six of these can potentially become 
phosphorylated [4,5]. Collectively, these form three copies of 
the so-called immunoreceptor tyrosine-based activation motif 
(ITAM), which has the sequence Y-X-X-I/L-(X6_s)-Y-X-X-I/ 
L (for recent reviews on ITAM-mediated signaling in cells of 
the immune system, see [1,6,7]). ZAP-70 subsequently binds 
specifically to the doubly phosphorylated forms of the TCR 
and CD3e ITAMs [8,9], events which require both of its phos- 
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photyrosine-binding SH2 domains [10-12]. ZAP-70 subse- 
quently becomes tyrosine phosphorylated on Y492 and 
Y493 [13]. These events require another T cell PTK, possibly 
Lck (a member of the Src PTK family), with phosphorylation 
of ZAP-70 on Y493 being essential its catalytic activation 
[14,15]. Should any of these events be blocked, or should a 
loss of function mutation or deletion occur in either the ZAP- 
70 or TCR ~ genes, T cell function is abrogated significantly 
[16-24]. Such gene mutations/deletions are known to cause 
impairment of thymic selection of T cells [16-20] as well as 
severe combined immune deficiency disorders [21-23] in both 
mice and humans. The elucidation of the roles played by 
ZAP-70 and TCR ~ in TCR signaling is thus an essential 
step towards the understanding of such diseases. 
Besides ZAP-70 and Lck, two other T cell PTKs are acti- 
vated via TCR or co-receptor stimulation, namely Fyn (an- 
other Src-family PTK) and Itk (reviewed in [1 3]). The anal- 
ysis of changes in the catalytic activities of these enzymes is 
thus an important step in any investigation i to the role of 
these molecules in this process. Typically, such analyses are 
performed by isolating the kinase via immunoprecipitation 
from cell lysates prepared under different stimulation condi- 
tions, and then assaying its activity towards an exogenous 
(usually non-physiological) in vitro substrate. Unfortunately 
to date, only very few in vitro substrates for ZAP-70 have 
been identified, with none being exclusively phosphorylated 
by this kinase [25]. Interpretation of such data is thus often 
complicated by the co-precipitation f other kinases. ZAP-70 
has been shown to associate with Lck in an activation-de- 
pendent manner [26] and is active towards a much narrower 
range of substrates than Lck [25]. Indeed, it has recently been 
shown that ZAP-70 can also associate with Fyn in vivo [27]. It 
thus seems clear that a substrate capable of distinguishing 
between the activities of ZAP-70 and the other prominent T
cell PTKs would be useful. 
In the few studies that have been performed on ZAP-70 
activation in T cells, a preferred substrate has been an ex- 
pressed form of the cytoplasmic fragment of the erythrocyte 
band 3 ion-transport protein (cfb3) [14,15,24,28], a molecule 
previously identified as a substrate for the ZAP-70-related 
PTK, Syk [29]. Using a selection of expressed PTKs, we 
have here determined that while both ZAP-70 and Lck can 
phosphorylate cfb3 in vitro, they do so at different sites. We 
went on to identify ZAP-70 and Lck specific sites of phos- 
phorylation, both in the N-terminal region of cfb3. Based on 
this information, we synthesized a peptide substrate which we 
have shown to be well phosphorylated by ZAP-70, but not by 
expressed versions of the T cell PTKs, Lck and Itk. This 
peptide, which we have termed ZAPstrate, should thus prove 
useful in the determination of the role played by ZAP-70 in 
the process of T cell activation. 
All rights reserved. 
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2. Materials and methods 
2.1. Materials 
cfb3 protein was expressed and purified as previously described [30]. 
Synthetic peptides containing the Lck autophosphorylation site 
(Y394) and the entire cytoplasmic domain (residues 52-164) of the 
murine TCR ~ subunit have already been described [31], and were 
provided by Dr. I. Clark Lewis (University of B.C., Vancouver, Can- 
ada). Peptides corresponding to residues 2-30 and 2-16 of cfb3 
(EELQDDYEDMMEENLEQEEYEDPDIPESQKK and EELQD- 
DYEDMMEENLKK, respectively), both with two additional C- 
terminal ysine residues, were synthesized by the peptide synthesis 
facility in the Dept. of Immunology, University of Washington. Mye- 
lin basic protein (MBP) was purchased from Sigma. 
Monoclonal antibodies were purified from the culture supernatant 
of 9El0 hybridoma cells (ATCC) as described in [32], using protein-G 
Sepharose (Pharmacia) in place of protein-A. Baculovirally expressed 
wild-type Lck was partially purified from Sf9 cells as described [31], 
and High Five cells expressing myc-tagged ZAP-70 were produced as 
described [25]. A GST fusion protein of the Itk kinase domain (Itk- 
KD-GST) was expressed in Sf9 cells according to the manufacturer's 
instructions, utilizing the BaculoGold baculovirus expression system 
(Pharmingen), and purified on a glutathione agarose column (Phar- 
macia) according to standard procedures. 
All chemicals and solvents were purchased from J.T. Baker, unless 
otherwise indicated. Reagents for peptide sequencing were purchased 
from Applied Biosystems. Chemicals and equipment for gel electro- 
phoresis was obtained from BioRad. Autoradiography was performed 
using Kodak X-OMAT film and a Kodak X-OMAT 480 RA proces- 
sor. Cerenkov and liquid scintillation counting was performed on a 
Beckman LS 6500. 
2.2. In vitro phosphorylation of cfb3 protein and cfb3 (2~0) with 
ZAP-70 and Lck 
Lysate from baculovirus-infected High Five cells expressing a myc- 
tagged recombinant human ZAP-70 was produced as previously de- 
scribed [13]. 50 I.tl of a cytosolic extract was diluted to 500 I.tl with 25 
mM Tris pH 7.5, 10% glycerol, 2 mM EDTA, 0.1% Nonidet P-40, on 
ice. The ZAP-70 was precipitated by the addition of 10 gg of 9El0 
(which recognizes the C-terminal myc affinity tag) for 2 h at 4°C with 
constant mixing, followed by 30 gl of a 50% slurry of protein-G 
Sepharose for 1 h at 4°C. Precipitates were washed 3 × with 1 ml 
of cold 50 mM Tris pH 7.5, 150 mM NaCI, 2 mM EDTA, 0.5% 
Triton X-100. 
Phosphorylation was performed by adding 50 gl kinase assay buffer 
(25 mM Tris pH 7.5, 10 mM MnCI2, 0.1% Nonidet P-40, 1 mM DTT, 
1 mM ATP (Sigma), with [7-32p]ATP (NEN DuPont) added to 1100 
dpm/pmol if required) to 25 gg of cfb3 (2-30) peptide and either the 
ZAP-70 precipitates or 5 I.tl of partially purified baculovirally ex- 
pressed Lck [31]. Kinase reactions were incubated for 1 h at 30°C 
and phosphopeptides repurified by HPLC. For phosphorylation of
the full-length cfb3 protein, preparation of kinases and reaction con- 
ditions were as described above, except hat DTT was absent from the 
kinase reaction, [7-32p]ATP was added to 440 dpm/pmol and 10 gg of 
substrate (cfb3) was added. 
2.3. Substrate comparisons for T cell PTKs ZAP-70, Lck and ltk 
ZAP-70 precipitates were produced using 9El0 antibodies and pro- 
tein-G Sepharose as outlined above, except hat only 12 gl of lysate 
was used per sample. Phosphorylation assay buffer was 50 mM Tris 
pH 7.5, 10 mM MnC12, 0.1% Triton X-100, 250 gM ATP, with [y- 
32P]ATP added to 1760 dpm/pmol. Substrates were then added to 
aliquots of assay buffer and kept on ice until required. TCR 4, 
cfb3, Lck Y394 and cfb3 (2-16) peptides were made to a final con- 
centration of 0.8 mg/ml, MBP was made to 0.4 mg/ml. 
For ZAP-70 kinase assays, 25 p.l of each substrate was added to a 
separate ZAP-70 precipitate (each substrate in triplicate) with the 
control reaction containing no substrate (i.e. kinase and ATP only). 
Reactions were performed at 300C for 10 min with frequent mixing of 
the beads. 22 gl of each reaction (supernatant) was transferred to 
squares of p81 phosphocellulose paper (Whatman), dried in air for 
1 min, and then washed extensively in 1% orthophosphoric a id. For 
the other kinases, the substrate/assay buffer mixtures were split into 
25 gl aliquots (three samples per kinase). 2.5 gl of partially purified 
wild-type Lck or Itk-KD-GST was added to each set of substrates. 
Incubation was again at 30°C for 10 rain, followed by transfer to p81 
paper and washing with orthophosphoric a id. Radioactive incorpora- 
tion was assessed by liquid scintillation counting of the p81 paper 
squares [31]. 
2.4. Two-dimensional phosphopeptide mapping 
Phosphopeptide mapping of phosphorylated cfb3 was performed on 
electroblotted proteins essentially as described [13] with the following 
modifications: Enzymatic leavage was carried out overnight at 37°C 
with 1 gg Asp-N endoprotease (Boehringer Mannheim) per sample, in 
1% ammonium bicarbonate pH 7.5, and electrophoresis in the first 
dimension was performed on a Hunter thin-layer peptide mapping 
system (C.B.S. Scientific Co.) using an EC-555 power pack (E-C Ap- 
paratus Corp.) at 750 V and 8°C for 55 min. 
2.5. HPLC and MS analyses 
Labeled peptide samples were acidified with 1/10th volume of 10% 
triftuoroacetic acid (TFA) (Applied Biosystems) and injected into a 
Waters 600E system equipped with a 490E detector. Separation was 
performed on a Vydac C4 column (4.6 × 250 mm) at a flow rate of 0.6 
ml/min. UV absorbance was recorded at 214 nm. The column was 
washed isocratically with buffer A (0.1% TFA). A 5 min gradient 
from 0 to 25% buffer B (70% acetonitrile, 0.08% TFA) was performed, 
followed by the main separating radient of 25 to 45% buffer B over 
30 min. The column was washed in 100% buffer B and re-equilibrated 
in buffer A prior to subsequent analyses. Mass spectrometry (MS) was 
performed on a prototype Sciex electrospray ionization (ESI) single 
quadrupole mass spectrometer. 
2.6. Radiosequencing 
Radiosequencing via solid-phase Edman degradation was per- 
formed essentially as described [33]. Briefly, following covalent cou- 
+ 
4- 
Fig. 1. 2D phosphopeptide mapping of cfb3 phosphorylated with 
Lck and ZAP-70. cfb3 protein was phosphorylated with either Lck 
or ZAP-70 (as indicated), as described under Section 2. Samples 
were subjected to SDS-PAGE, transferred to nitrocellulose and 
phospho-cfb3 identified via autoradiography. Following in situ 
cleavage with Asp-N, phosphorylated peptides were resolved on 2D 
phosphopeptide maps and visualized via autoradiography. The loca- 
tion of the sample origin (O) and the position of the positive (+) 
and negative ( - )  electrodes during electrophoresis are indicated. 
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pling to arylamine discs (Millipore) of peptide peaks recovered from 
the HPLC, the Edman degradation was performed on an Applied 
Biosystems 477A peptide sequencer, with eluate emerging from the 
sequencer following each cleavage cycle being diverted to a fraction 
collector, followed by analysis by liquid scintillation counting. 
3. Results and discussion 
3.1. Identification of a ZAP-70-specific phosphorylation site on 
cfb3 
Previous observations had shown that while both ZAP-70 
and Lck were capable of phosphorylating cfb3, it was a better 
substrate for ZAP-70 [25]. Thus ZAP-70 may be recognizing a 
site(s) on cfb3 not recognized by Lck, and if so, its identifica- 
tion could form the basis of a ZAP-70-specific substrate. To 
investigate this possibility, cfb3 was phosphorylated in the 
presence of [y-3zP]ATP with either recombinant ZAP-70 or 
Lck, and subjected to phosphopeptide mapping (Fig. 1). Since 
previous reports had shown that the ZAP-70-related PTK, 
Syk, was capable of phosphorylating cfb3 at its N-terminus 
[29], and since cfb3 has a very acidic N-terminus with no 
tryptic cleavage sites, we chose to perform digests with Asp- 
N. As can be seen in Fig. 1, the ZAP-70- and Lck-derived 
maps produced several spots which were either unique, or 
significantly more intense with one kinase over the other (ar- 
rowheads). In particular, ZAP-70 phosphorylation of cfb3 
produced one very intense spot that was only weakly apparent 
when using Lck. 
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We knew that a peptide derived from the C-terminus of ct- 
tubulin was a good in vitro substrate for ZAP-70 [25]. The 
sequence around the phosphorylated tyrosine in this peptide 
(ALEKDYEEVGV) is similar to that surrounding the two N- 
terminal tyrosines at Y8 and Y21 of cfb3 (ELQD- 
DYEDMME and LEQEEYEDPDI, respectively). Previous 
reports had also identified the N-terminus of cfb3 as contain- 
ing the primary phosphorylation site(s) of Syk [29]. We thus 
utilized a synthetic peptide corresponding to residues 2-30 of 
cfb3 as a potential substrate for Lck and ZAP-70. The peptide 
was phosphorylated with either ZAP-70 or Lck, and phospho- 
peptides and unphosphorylated peptide species separated by 
HPLC. 
As can be seen in Fig. 2A, ZAP-70 and Lck phosphoryla- 
tion of cfb3 (2-30) produced ifferent HPLC profiles. Peak 1 
had the same retention time as unphosphorylated peptide run 
alone (not shown), whereas peaks 2 and 3 were products of 
the kinase reaction. We thus subjected all three peaks to elec- 
trospray ionization mass spectrometry (ESI-MS) (Fig. 2B). 
Peak 1 yielded a major ion species at a mass to charge ratio 
(m/z) of 1284. This correlated with the expected value for the 
triply charged ([M+3H] 3+) ion of the non-phosphorylated 
peptide (Mw=3849). ESI-MS analyses of peaks 2 and 3 
gave essentially the same result (re~z= 1311 and 1310.5, re- 
spectively) which correlated to the expected [M+3H] a+ value 
for a singly phosphorylated form of the cfb3 (2-30) peptide 
(M~¢ -- 3929). Peaks labeled 1 and 3 had essentially identical 
ESI-MS spectra when generated by either kinase (not shown), 
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Fig. 2. HPLC and ESI-MS analyses of cfb3 (2-30) peptide phosphorylated with Lck and ZAP-70. (A) cfb3 (2-30) peptide was phosphorylated 
with either baculovirally expressed ZAP-70 or Lck and phosphopeptides were then separated from non-phosphorylated peptide via HPLC on a 
C4 column (4.6× 250 rnm) as described under Section 2. Absorbance traces (at 214 nm) for the region of the gradient where peptides eluted 
are shown, along with the acetonitrile buffer concentrations recorded at the pump heads. (B) ESI-MS data for the peptide peaks labeled 1-3 in 
(A) were recorded. Only triply charged ([M+3H] a+) peptide species were observed. Only the region of the spectra is shown where cfb3 (2-30) 
peptide peaks would be observed (m/z = 900-1500) and signal intensities are given relative to the largest observed signal present in the full spec- 
trum. 
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Fig. 3. Radiosequencing of cfb3 (2-30) peptide phosphorylated with 
Lck and ZAP-70. cfb3 (2-30) peptide was phosphorylated with 
either baculovirally expressed ZAP-70 or Lck and repurified by 
HPLC exactly as shown in Fig. 2, except for the addition of [7- 
3~p]ATP to the kinase reactions. The ZAP-70 and Lck-derived sin- 
gly phosphorylated peptide species (Fig. 2, peaks 2 and 3, respec- 
tively) were covalently attached to arylamine membrane discs and 
subjected to radiosequencing viasolid-phase Edman degradation as 
described [33]. Total eluate emerging from the sequencer following 
each cleavage cycle was diverted to a fraction collector and analyzed 
by liquid scintillation counting. The results are displayed graphically 
against the sequence of the cfb3 (2-30) peptide. 
those shown in Fig. 2B being from the Lck phosphorylation 
reaction. 
The results hown in Fig. 2 strongly suggested that ZAP-70 
and Lck were selectively phosphorylating different tyrosines in 
cfb3 (2-30). To determine which kinase was phosphorylating 
which tyrosine, cfb3 (2-30) was again phosphorylated by the 
two PTKs, only additionally in the presence of [7-a~p]ATP. 
The singly phosphorylated peptides were again purified by 
HPLC as shown in Fig. 2, and subjected to solid-phase Ed- 
man degradation. Sequencing reaction products resulting 
from each cycle were collected and analyzed by liquid scintil- 
lation counting (Fig. 3). The ZAP-70-phosphorylated peptide 
(Fig. 2, peak 2) showed a significant burst in extracted radio- 
active counts at cycle 7 (corresponding to Y8 of cfb3) with no 
counts above background extracted at cycle 20 (Y21 of cfb3). 
The Lck-phosphorylated peptide (Fig. 2, peak 3) yielded no 
radioactivity above background at cycle 7, giving an increase 
instead at cycle 20. Thus, it was clear that ZAP-70 can phos- 
phorylate cfb3 at Y8, a residue not phosphorylated by Lck. 
These data are in agreement with previous observations that a 
principal site of phosphorylation on cfb3 in vivo is on Y8 
[34,35] and is likely attributable to the ZAP-70-related Syk 
PTK, which is expressed in erythrocytes [29]. 
3.2. Evaluation o f  a cfb3-derived peptide as a ZAP-70-specific 
substrate 
We already knew that the whole cfb3 protein could be 
phosphorylated by both ZAP-70 and Lck [25], though it 
was a relatively poor substrate for Lck. However, in light of 
recent observations that ZAP-70 can associate in vivo with 
Lck and the Lck-related PTK Fyn [26,27], cfb3 is not an ideal 
substrate for the evaluation of changes in the activity of ZAP- 
70 following T cell activation. Since such assays for ZAP-70 
activity would normally involve immunoprecipitation f l- 
lowed by an in vitro kinase assay, the concurrent activation 
of both Lck and/or Fyn and their association with ZAP-70 
could make such data misleading. Although not known to 
associate with either ZAP-70, Lck or Fyn, the Itk T cell 
PTK becomes activated [36] and might also be capable of 
interfering in such assays. The inability of Lck to phosphor- 
ylate Y8 of cfb3 might enable the construction of a peptide 
substrate specific for ZAP-70. 
We thus used a synthetic peptide based around Y8 of cfb3, 
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Fig. 4. Comparison of cfb3 (2-16) peptide with other PTK substrates using the T cell PTKs Lck, Itk and ZAP-70. MBP, TCR ~, cfb3, Lck 
Y394 peptide and cfb3 (2-16) peptide were phosphorylated in the presence of [7-32P]ATP with either wild-type Lck (w.t. Lck), a GST fusion 
protein of the Itk kinase domain (Itk-KD-GST), or ZAP-70 as indicated. Autophosphorylation controls (no added substrate) were also per- 
formed for each kinase. Phosphorylation was for 10 min at 30°C, reactions being stopped by spotting onto p81 paper and washing in 1% 
orthophosphoric a id. Radioactive incorporation i to the substrate was determined via liquid scintillation counting and is represented relative 
to the largest peak for each kinase. Data shown are the mean of three measurements, with the standard eviation given as the error. 
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with two additional C-terminal lysine residues added (desig- 
nated cfb3 (2-16)) to facilitate binding to the phosphocellu- 
lose paper frequently used in protein kinase assays. We tested 
a selection of known PTK substrates, namely MBP, TCR 
(residues 52-164, containing all three ITAMs), cfb3, a peptide 
based on the Lck autophosphorylation site (Y394) and the 
cfb3 (2-16) peptide, as potential substrates for a selection of 
baculovirally expressed T cell PTK-derived molecules. We 
used the myc-tagged ZAP-70, wild-type Lck and a GST fusion 
protein containing the Itk kinase domain (Itk-KD-GST), 
which represent three of the major classes of non-receptor 
PTKs involved in T cell signaling. We screened the three ki- 
nases against each substrate, with an autophosphorylation 
control (no added substrate) for each (Fig. 4). 
In agreement with our previous observations, MBP, TCR 
and Lck Y394 were phosphorylated by Lck and Irk, but not 
ZAP-70 [25]. Also in agreement with our previous observa- 
tions, cfb3 was phosphorylated relatively well by ZAP-70, 
weakly by Lck, and very poorly by Itk-KD-GST. However, 
the cfb3 (2-16) peptide was a good substrate for ZAP-70, and 
was barely phosphorylated at all by the other PTKs over 
respective controls. We observed increased variation between 
the individual data points for the ZAP-70 reactions, which 
can likely be attributed to additional experimental steps, re- 
quired for the immunoprecipitation f the kinase, over the 
other molecules, which were used in purified form. 
It is possible that the PTKs isolated from T cells will exhibit 
different substrate specificities to their expressed counterparts 
used here. However, the baculovirus ystem, in contrast o 
bacterial expression systems, has proven itself to be the super- 
ior system for the expression of active PTKs, and in the cases 
of ZAP-70 and Lck, the numerous tudies to date on their 
catalytic activities have shown the in vivo-derived and ex- 
pressed kinases to behave very similarly. It should also be 
noted here that while previous reports have shown that the 
epidermal growth factor receptor (EGFR) PTK will also 
phosphorylate cfb3 at Y8 [37,38], T cells do not express trans- 
membrane PTKs of the EGFR family. Thus under typical 
ZAP-70 immunoprecipitation conditions, the co-precipitation 
of such receptor PTKs should not be a cause for concern in 
the use of the cfb3 (2-16) peptide as an assay for ZAP-70 
activity in T cells. 
With the identification of immunodeficiency disorders in 
both mice and humans correlated to mutations in the ZAP- 
70 gene or its promoter, the elucidation of ZAP-70 regulation 
and function is thus a critical step on the path to the deter- 
mination of treatments for such disorders. Indeed, we have 
already shown that blocking normal ZAP-70 function with a 
peptide analog that disrupts its natural in vivo interaction 
with TCR ~ severely impairs TCR-mediated signaling [24]. 
The availability of the cfb3 (2-16) peptide, or ZAPstrate as 
we have named it, should thus be a useful tool in the deter- 
mination of the role played by this important PTK in TCR- 
mediated signaling. 
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